Bruker Daltonics and HealthLinx Expand Biomarker Discovery Collaboration.

MELBOURNE, Australia -- HealthLinx Limited (ASX:HTX) today announced the signing of a joint patent agreement with Bruker Daltonics Inc. to further develop biomarkers that have been discovered under an existing collaboration between the two life science companies. These biomarkers are candidates for a number of pregnancy complications based on scientific research using Bruker Daltonics' ClinProt[TM] platform. Associate Professor Greg Rice of HealthLinx and Dr. Gongyi Shi from Bruker Daltonics' Fremont, California, USA applications laboratory discovered the biomarkers as a result of the two companies' on-going collaboration and, accordingly, both will be recognised as co-inventors.

Under the new agreement, Bruker Daltonics and HealthLinx will file a joint PCT patent application and share costs associated with the patent and development of the biomarkers. The patent will focus on the use of the biomarkers as a diagnostic test for the detection of "Complications of Pregnancy". It is envisaged that the "test" will be a blood test performed at the first antenatal visit and/or subsequently during pregnancy. The test will seek to diagnose women with a predisposition to a number of complications in pregnancy including pre-eclampsia, pre-term labour, miscarriage and gestational diabetes. Women will be classified as either having a high risk or a low risk of developing complications of pregnancy, allowing the gynecologist and/or general practitioner to undertake more appropriate management and/or intervention strategies during the pregnancy to improve outcomes for both mother and baby.

Under the agreement, Bruker Daltonics will retain marketing rights for the test in Europe, UK, Africa and South America, while HealthLinx will retain marketing rights in Australia, New Zealand and Asia. The two companies will jointly market the test in the United States and Canada. Furthermore, the two companies will work together to complete the Phase II trial for the ClinProt-based test. HealthLinx will retain world-wide exclusivity for any ELISA/Multiplex based test that may be developed in the future.

HealthLinx' CEO, Mr Nick Gatsios, said, "The two companies have been working together for the past 12 months on obtaining Phase I validation of the biomarkers and we are excited about the opportunity this presents both companies."

Dr. Gary Kruppa, Vice President of Bruker Daltonics, stated, "This work represents a further validation of our ClinProt platform for the discovery and identification of biomarkers. We are also excited about the success of this collaboration to date, and the opportunity that the development of these biomarkers presents. "

ABOUT HEALTHLINX LIMITED (ASX- HTX)

HealthLinx has secured world-wide, exclusive licenses for biomarkers that have application within the predictive diagnostic market-space, in particular for the diagnosis of cancer. Currently, the company is entering Phase II biomarker trials for two diagnostic products and has significant IP in Protein Depletion Technologies that depletes serum and/or biological fluids of the top 12 proteins. The company also has some early pre-clinical therapeutic peptides in development stage and is supported by a strong development pipeline targeting disease states with un-met market needs.

ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)

Bruker BioSciences Corporation in Billerica, Massachusetts is the parent company of Bruker AXS Inc., Bruker Daltonics Inc. and Bruker Optics, Inc. Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis and spark-OES tools. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry, and also offers a broad line of chemical, biological, radiological and nuclear (CBRN) detection products for homeland security. Bruker Optics is a leading developer, manufacturer and provider of research, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technology. For more information, please visit www.bruker-biosciences.com

CAUTIONARY STATEMENT OF BRUKER BIOSCIENCES

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the companies' reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the companies' products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2005, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements.